3rd NEW HORIZONS IN IMMUNOTHERAPY
FOR HEAD AND NECK CANCER

Friday, June 15, 2018 & Saturday, June 16, 2018

Sponsored by UPMC Center for Continuing Education in the Health Sciences and
UPMC Hillman Cancer Center

Renaissance Pittsburgh Hotel
107 6th Street
Pittsburgh, PA  15222

Course Directors
Robert L. Ferris, MD, PhD
R. Bryan Bell, MD, DDS, FACS
Ezra Cohen, MD, FRCPS, FASCO

Intent and Overview
Cancer immunotherapy has rapidly advanced in recent years with two FDA approved agents in the past year. Given the need to disseminate the science and clinical data underlying the clinical benefit observed, and to increase awareness of the role of the immune system in head and neck cancer therapy, as a single modality or in combination with conventional therapies (chemotherapy and radiation), this interactive course has been developed and enhanced from prior meetings and attendee input.

Objectives
1. To provide a forum for leaders in the field of head and neck immuno-oncology to exchange ideas.
2. To provide an opportunity for those with emerging interest in head and neck immuno-oncology to gain an understanding of the currently available immunotherapy agents and a rationale for ongoing and future clinical trials.

Who Should Attend
This conference is designed for leaders in head and neck cancer who are interested in the advancements in the field of immunotherapy for the treatment of cancer patients.

Medical oncologists, radiation oncologists, otolaryngologists, oral surgeons, primary care physicians, pediatricians, family practitioners, nurse practitioners, physician assistants, residents, audiologists, speech therapists, and other interested health care professionals.
Special Needs
Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by e-mailing Brittni Prosdocimo at bittnerb@upmc.edu.

CME Accreditation and Designation Statement
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded 1.4 continuing education units (CEU’s) which are equal to 14.0 contact hours.

Registration

Registration Fees
- $250 “Early Bird” physician registration - Early Bird registration is available until April 30, 2018.
- $300 Regular physician registration - registration on or after May 1, 2018
- $100 – Advanced Practice Providers
- Tuition fee is waived for all nurses, residents, fellows, international visiting scholars, and medical students, but registration is still required.

Payment is due at time of registration. Payments will be made online with registration at https://ccehs.upmc.com/home.jsf

Cancellations
All cancellations must be in writing and sent to Brittni Prosdocimo via e-mail at bittnerb@upmc.edu. Tuition for cancellations postmarked or date stamped before June 1, 2018 will be completely refunded. No refunds will be made on or after June 1, 2018. “No shows” are not eligible for refunds.

The UPMC Center for Continuing Education in the Health Sciences reserves the right to cancel this program if sufficient registrations are not received. In the case of cancellation, the department will fully refund registration fees.

Accommodations
A block of rooms are being held at the Renaissance Pittsburgh Hotel. Please contact the hotel to reserve a room by Wednesday, May 23, 2018:

Renaissance Pittsburgh Hotel
107 6th Street
Pittsburgh, PA  15222
1-866-915-0479
## SCHEDULE

*Day 1 of 2: Friday, June 15, 2018*

### SESSION 1: BIOMARKERS AND ANTI-PD-1/PD-L1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 – 7:55 am</td>
<td>Registration/Breakfast/Exhibits (Visit Exhibitors/Vendors)</td>
</tr>
</tbody>
</table>
| 7:55 – 8:00 am | Welcome  
  *Robert L. Ferris, MD, PhD*                                                          |
| 8:00 – 8:25 am | Current State of Immunotherapy Trials for Head and Neck Cancer  
  *Ezra Cohen, MD, FRCPC, FASCO*                                                        |
| 8:25 – 8:35 am | Q&A                                                                                       |
| 8:35 – 9:15 am | **Keynote:** TCR-Directed Therapies for HPV-Associated Cancer  
  *Christian S. Hinrichs, MD*                                                            |
| 9:15 – 9:25 am | Q&A                                                                                       |
| 9:25 – 9:50 am | PD1/PDL1 and Combination Targeting  
  *Dan P. Zandberg, MD*                                                                    |
| 9:50 – 10:00 am | Q&A                                                                                      |
| 10:00 – 10:25 am | Next Generation I-O Combinations  
  *Rom S. Leidner, MD*                                                                    |
| 10:25 – 10:55 am | Biomarkers of Response to Successful Anti-PD1 Therapy  
  *Laura QM Chow, MD, FRCPC*                                                             |
| 10:55 – 11:10 am | Q&A                                                                                      |
| 11:10 – 11:35 am | Neoadjuvant Trial Design: Anti-PD1 Prior to Surgery for HNSCC  
  *Ravindra Uppaluri, MD, PhD, FACS*                                                     |
| 11:35 – 12:00 pm | PD1 Blockade in Cutaneous SCC  
  *Dan P. Zandberg, MD*                                                                   |
| 12:00 – 12:10 pm | Q&A                                                                                      |
| 12:10 – 12:50 pm | Lunch/Exhibits (Visit Exhibitors/Vendors)                                                 |
| 12:50 – 1:10 pm | Personalized Neoantigen Vaccines for HNSCC  
  *Ezra Cohen, MD, FRCPC, FASCO*                                                         |
Day 1 of 2: Friday, June 15, 2018

SESSION 2: MODULATING THE TUMOR MICROENVIRONMENT

1:10 – 1:35 pm  HNSCC Immunogenomics - Moving Beyond TMB  
Luc G.T. Morris, MD, MSc

1:35 – 1:45 pm  Q&A

1:45 – 2:10 pm  New Applications of Multispectral Imaging in Head and Neck Cancer  
Bernard A. Fox, PhD

2:10 – 2:35 pm  Targeting the Tumor Microenvironment to Enhance Efficacy of Chemo- and Immuno-Radiotherapy  
Andrew Sikora, MD, PhD

2:35 – 2:55 pm  STING and Other Inflammatory Agonists in HNSCC Immunotherapy  
Young Jun Kim, MD, PhD

2:55 – 3:10 pm  Break/Exhibits (Visit Exhibitors/Vendors)

3:10 – 3:40 pm  **Keynote Lecture:** Mechanism and Application of OX40 Targeting in Cancer Patients  
Andrew D. Weinberg, PhD

3:40 – 3:55 pm  Q&A

3:55 – 4:20 pm  Targeting Stem Cells and Immunotherapy  
John B. Sunwoo, MD

4:20 – 4:45 pm  Altering Macrophage Polarity in HNSCC  
Judith A. Varner, PhD

4:45 – 4:55 pm  Q&A

4:55 pm  Adjournment Day 1 of 2

5:30 pm  Reception – Renaissance Hotel
Day 2 of 2: Saturday, June 16, 2018

SESSION 3: STRATEGIES FOR RATIONAL COMBINATIONS

7:30 – 8:00 am  Breakfast/Exhibits (Visit Exhibitors/Vendors)

8:00 – 8:25 am  Modulating the Tumor Microenvironment to Enhance the Effectiveness of Surgery  
*R. Bryan Bell, MD, DDS, FACS*

8:25 – 8:50 am  Metabolic Changes in the TME Affect Immunotherapy  
*Greg M. Delgoffe, PhD*

8:50 – 9:15 am  Harnessing Genomics to Enhance Immunotherapy: Building a Neoadjuvant: Neoantigen Platform for Patient Specific Immunotherapy  
*Nadeem Riaz, MD, MSc*

9:15 – 9:25 am  Q&A

9:25 – 9:50 am  **Keynote:** Treg Stability and Harnessing the TME for Immunotherapy  
*Dario Vignali, PhD*

9:50 – 10:00 am  Q&A

10:00 – 10:15 am  Break/Exhibits (Visit Exhibitors/Vendors)

10:15 – 10:55 am  Radiation Induced Modulation of Tumor Vasculature and T-cell Infiltration  
*Andrew Sharabi, MD, PhD*

10:55 – 11:05 am  Role of Tumor Infiltrating B Cells in Head and Neck Cancer  
*Tullia C. Bruno, PhD*

11:05 – 11:15 am  Q&A

11:15 – 11:35 am  Intersection of DNA Damage and Immune Escape: Immune and Genomic Checkpoints  
*Christopher J. Bakkenist, PhD*

11:35 – 12:00 pm  Radiation and Immunotherapy Using DNA Damage Inhibition  
*David A. Clump, MD, PhD*

12:00 – 12:10 pm  Q&A

12:10 – 1:00 pm  Lunch/Exhibits (Visit Exhibitors/Vendors)
Day 2 of 2: Saturday, June 16, 2018

SESSION 4: NEOANTIGENS AND ADOPTIVE CELL THERAPY

1:00 – 1:25 pm
Immunocompetent HNSCC Mouse Models
J. Silvio Gutkind, PhD

1:25 – 1:50 pm
Chemoimmunotherapy: Risks, Benefits and Alternatives
Nicole C. Schmitt, MD

1:50 – 2:00 pm
Q&A

2:00 – 2:25 pm
Sensitizing HNSCC to immune checkpoint blockade through G2/M cell cycle checkpoint abrogation
Clint T. Allen, MD, FACS

2:25 – 2:50 pm
TILs to TCRs: A Strategy for Developing Adoptive Immunotherapy for Solid Tumors
Udai S. Kammula, MD, FACS

2:50 – 3:00 pm
Q&A

3:00 pm
Adjournment Day 2 of 2

Course Directors

Robert L. Ferris, MD, PhD
Hillman Professor of Oncology and Director
UPMC Hillman Cancer Center
Associate Vice-Chancellor for Cancer Research
Co-Director, Tumor Microenvironment Center
Professor of Otolaryngology, of Immunology, and of Radiation Oncology
University of Pittsburgh School of Medicine
Pittsburgh, PA

R. Bryan Bell, MD, DDS, FACS
Medical Director, Providence Oral, Head and Neck Cancer Program and Clinic
Earle A. Chiles Research Institute in the Robert W. Franz Cancer Center at Providence
Portland Medical Center
Portland, OR

Ezra Cohen, MD, FRCPC, FASCO
Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, UC San Diego
Co-director, San Diego Center for Precision Immunotherapy
Associate Director for Translational Science, Moores Cancer Center
Co-leader, Solid Tumor Therapeutics Program
Co-director, Head and Neck Cancer Center of Excellence
San Diego, CA
Guest Faculty

Clint T. Allen, MD, FACS  
Associate Professor  
Johns Hopkins School of Medicine and The National Institutes of Health  
Bethesda, MD

Laura QM Chow, MD, FRCPC  
Associate Professor  
University of Washington  
Seattle, WA

Bernard A. Fox, PhD  
Harder Family Chair for Cancer Research, Member and Chief, Laboratory of Molecular and Tumor Immunology  
Earle A Chiles Research Institute  
Robert W. Franz Cancer Center  
Providence Portland Medical Center  
Portland, OR

J. Silvio Gutkind, PhD  
Professor, Department of Pharmacology  
Associate Director of Basic Science  
UC San Diego Moores Cancer Center  
La Jolla, CA

Christian S. Hinrichs, MD  
Investigator, Lasker Scholar  
National Cancer Institute  
Bethesda, MD

Young Jun Kim, MD, PhD, FACS  
Amy & Barry Baker Endowed Chair  
Co-Leader, Translational Research & Interventional Oncology  
Director, Head & Neck Oncologic Research, Vanderbilt-Ingram Cancer Center  
Associate Professor, Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center  
Vanderbilt University Medical Center  
Nashville, TN

Rom S. Leidner, MD  
Co-Director, Providence Oral, Head, and Neck Cancer Program  
Assistant Member, Earle A. Chiles Research Institute  
Portland, OR

Luc G.T. Morris, MD, MSc  
Adlerian Chair and Associate Professor of Surgery  
Associate Director, Immunogenomics and Precision Oncology Platform  
Memorial Sloan Kettering Cancer Center  
New York, NY

Nadeem Riaz, MD, MSc  
Assistant Attending, Department of Radiation Oncology  
Associate Director, Immunogenomics and Precision Oncology Platform  
Memorial Sloan Kettering Cancer Center  
New York, NY

Nicole C. Schmit, MD  
Assistant Professor, Division of Head and Neck Surgery  
Department of Otolaryngology- Head and Neck Surgery  
Johns Hopkins University  
Baltimore, MD

Andrew Sharabi, MD, PhD  
Assistant Professor  
University of California at San Diego  
Radiation Medicine & Applied Sciences  
San Diego, CA

Andrew Sikora, MD, PhD  
Associate Professor and Caroline Weiss Law Translational Research Scholar  
Department of Otolaryngology, Baylor College of Medicine  
Houston, TX

John B. Sunwoo, MD  
Associate Professor  
Stanford University  
Stanford, CA

Ravindra Uppaluri, MD, PhD, FACS  
Director, Head and Neck Surgical Oncology, Chief, Division of Otolaryngology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School  
Boston, MA
Guest Faculty

Judith A. Varner, PhD  
Professor of Pathology and Medicine  
Moores Cancer Center  
University of California, San Diego  
La Jolla, CA

Andrew D. Weinberg, PhD  
Judy Ann Hartmann Endowed Chair for Cancer Immunology Research,  
Member and Chief, Laboratory of Basic Immunology  
Earle A Chiles Research Institute  
Robert W. Franz Cancer Center  
Providence Portland Medical Center  
Portland, OR

Local Faculty

Christopher J. Bakkenist, PhD  
Associate Professor of Radiation Oncology  
Vice Chair for Basic Science  
University of Pittsburgh, School of Medicine  
Pittsburgh, PA

Tullia Bruno, PhD  
Research Assistant Professor  
University of Pittsburgh  
Pittsburgh, PA

David A. Clump, MD, PhD  
Assistant Professor  
Department of Radiation Oncology  
UPMC Hillman Cancer Center  
Pittsburgh, PA

Greg M. Delgoffe, PhD  
Assistant Professor  
Tumor Microenvironment Center  
Department of Immunology  
University of Pittsburgh Cancer Institute  
UPMC Hillman Cancer Center  
Pittsburgh, PA

Udai S. Kammula, MD, FACS  
Director, Solid Tumor Cell Therapy Program  
UPMC Hillman Cancer Center  
Associate Professor, Division of Surgical Oncology  
University of Pittsburgh School of Medicine  
Pittsburgh, PA

Dario Vignali, PhD  
Frank Dixon Chair in Cancer Immunology  
Professor & Vice Chair of Immunology  
Leader of the Cancer Immunology Program  
Co-Director of the Tumor Microenvironment Center  
Scientific Director of Fondazione Ri.MED  
University of Pittsburgh  
Pittsburgh, PA

Dan P. Zandberg, MD  
Associate Professor of Medicine  
Director, Head and Neck Cancer and Thyroid Cancer Disease Sections  
Division of Hematology/Oncology  
UPMC Hillman Cancer Center  
Pittsburgh, PA

Faculty Disclosure  
All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.
Visit the Center for Continuing Education in the Health Sciences Web Site
The UPMC/Center for Continuing Education in the Health Sciences invites you to visit our web location. Receive information on CME programs, earn CME credits on the Internet, and access information about our formal courses and much more. Discover who we are and how you can contact us. Please visit our web location often to get updated information on upcoming programs: http://ccehs.upmc.com

The University of Pittsburgh is an affirmative action, equal opportunity institution.